Wall Street analysts have labeled seven biotech firms as potential takeover targets this year, as mentioned in GEN’s recent list, “Takeover Targets: Who Is First on the List?”. Of the seven, which do you think is the MOST likely target?
Poll Question:
Which company below do you think is the MOST likely to be acquired by a larger biotech partner or pharma giant?
Ariad Pharmaceuticals
30
Biomarin Pharmaceutical
33
Clovis Oncology
13
Incyte
29
Medivation
8
Regeneron Pharmaceuticals
34
Seattle Genetics
48
